Skip to main content
Christopher Norn

Christopher Norn

Co-Founder and CEO of Skape Bio, a biotech company using AI-driven protein design to create mini-protein drugs targeting GPCRs; PhD in Molecular Biophysics from Lund University.

Jul 22, 2026

6:32
How did these shape the founding vision for Scape and ultimately lead to the creation of the company?
6:39
Right.
6:39
So yeah, I, I was a postdoc with, with David Baker for, for, for three years.
6:44
Um, and towards the end of my, my postdoc, it was clear from all the AI innovation that was happening in the lab that protein design had become so precise, and the success rates were, were increasing, um, to the extent where, where we thought that maybe now it was possible to, to create modulators, uh, to create mini-proteins so precise that we could control the confirmation of not just the, the mini-protein, but also of the target that they, they would bind to.
7:14
Um, so with that idea in mind, together with the idea for the high throughput screening platform, that, that, that led to the, like, uh, idea of starting Scape, Scape Bio.
7:27
And where the BioInnovation fits in was in, uh, in shaping the vision.
7:32
So we had been discussing various different other projects, and they were, like, super keen on this particular, uh, project just because of the potential of it.
12:00
Where does AI contribute most meaningfully to that process today?

We value your privacy

We use cookies to understand how you use our platform and to improve your experience. Click “Accept All” to consent, or “Decline non-essential” to opt out of non-essential cookies. Read our Privacy Policy.